Trials / Unknown
UnknownNCT02226289
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
Phase II Study of Bevacizumab-containing Regimen in Patients With Metastatic Colorectal Cancer Who Failed to Cytotoxic Treatment
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), combined with fluoropyrimidine-based chemotherapy is now the standard first and second-line treatment for metastatic colorectal cancer. The efficacy of bevacizumab with cytotoxic agents in the third-line treatment of patients with mCRC is still unknown.
Detailed description
This is a single arm, phase II, open-labelled clinical trial to evaluate the safety and efficacy of bevacizumab combined with cytotoxic agents in the treatment of patients with mCRC progressing under all available cytotoxic chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | bevacizumab with the latest received cytotoxic regimen |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2014-08-27
- Last updated
- 2020-09-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02226289. Inclusion in this directory is not an endorsement.